Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Clinical Trial of Bi-weekly Dosing of Irofulven Plus Capecitabine in Patients With Anaplastic or Locally Advanced/Metastatic Differentiated Thyroid Cancer

NCT00124527 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT00124527
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00124527 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Clinical Trial of Bi-weekly Dosing of Irofulven Plus Capecitabine in Patients With Anaplastic or Locally Advanced/Metastatic Differentiated Thyroid Cancer
Lead sponsor
Eisai Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2005
Completion date
August 31, 2006
Enrollment
35
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid cancer